STRIDE Threat Modeling for Medical Devices

Master STRIDE threat modeling for medical devices. Learn to identify risks, meet FDA premarket requirements, and secure your MedTech ecosystem. Read our guide.

This guide is written for medical device manufacturers navigating STRIDE threat modeling medical devices. It is built from real submissions, FDA correspondence, and the standards reviewers actually cite. Use it as a working reference: read straight through, jump to the section that matches your current gap, or hand it to your engineering and regulatory leads as a checklist.

Introduction to STRIDE in the Medical Device Context

STRIDE is a threat classification framework, originally developed at Microsoft, that organizes potential attacks into six categories: spoofing, tampering, repudiation, information disclosure, denial of service, and elevation of privilege. In a medical device context, each category maps to a real patient-safety or data-protection consequence, a spoofed infusion pump command is not just an IT incident, it is a potential harm event. STRIDE gives engineering and regulatory teams a shared, repeatable vocabulary for walking through a device's architecture and asking "how could this be attacked" in a structured way, rather than relying on whichever vulnerabilities happen to come to mind. It is the most widely used threat modeling framework in FDA submissions today because it is systematic enough to produce defensible, reviewable documentation.

Why Threat Modeling is Critical for FDA Premarket Submissions

The FDA's premarket cybersecurity guidance explicitly expects manufacturers to identify and assess cybersecurity risks as part of the design process, and a documented threat model is the primary artifact reviewers use to judge whether that identification was done rigorously. Without one, a reviewer has no way to confirm you actually considered how an attacker could interact with your device's interfaces, and deficiency letters routinely ask manufacturers to "provide a threat model" when this evidence is missing. A well-built threat model also drives your security requirements, verification test cases, and risk assessment, making it the foundation the rest of your premarket cybersecurity package is built on rather than a standalone compliance exercise.

How STRIDE Fits into the Secure Product Development Framework (SPDF)

Inside an SPDF, STRIDE analysis happens early, during architecture and design, and its output (a categorized list of threats per component) becomes a direct input to your security risk assessment and to the security requirements you carry into verification and validation. As the design evolves, the threat model needs to be revisited, new interfaces, new third-party components, or new data flows can introduce threats that were not present in the original architecture. Manufacturers who treat the threat model as a living artifact, updated at each major design review, produce V&V evidence that clearly traces back to a specific identified threat, which is exactly the traceability chain FDA reviewers look for.

Breaking Down the STRIDE Categories for MedTech

Spoofing: Identity Risks in Connected Devices

Spoofing means an attacker impersonates a legitimate user, device, or system component to gain access they should not have, for example a rogue mobile app pretending to be the manufacturer's authorized companion app when pairing with an implantable device. In connected medical devices, spoofing risks concentrate around authentication between the device and its companion apps, cloud services, and any clinician-facing interfaces, especially where legacy protocols lack mutual authentication. Mitigations typically include mutual TLS, certificate-based device identity, and multi-factor authentication for clinician and administrative accounts, verified through penetration testing that specifically attempts impersonation attacks against each interface.

Tampering: Maintaining Data Integrity for Patient Safety

Tampering covers unauthorized modification of data, firmware, or configuration, ranging from an attacker altering a dosage value in transit to modifying firmware during an update to introduce malicious behavior. For medical devices, tampering risk is highest wherever data crosses a trust boundary without integrity protection, unsigned firmware updates, unauthenticated network messages, or writable configuration files on a device with physical access exposure. Effective controls include cryptographic signing of firmware images with signature verification before execution, checksums or MACs on clinical data in transit, and secure boot chains that prevent unauthorized code from running even with physical device access.

Repudiation: Audit Trails and Accountability

Repudiation risk exists when a user or system can perform an action, such as changing a device setting or accessing patient data, without a reliable, tamper-resistant record that ties the action to an identity and a timestamp. For regulated medical devices, this matters both for security incident investigation and for clinical accountability, if a dosage change cannot be attributed to a specific user, both patient safety review and forensic response after a breach become far harder. Mitigations center on centralized, append-only audit logging with cryptographic integrity protection, time synchronization across components, and log retention policies that survive a device reset or factory restore.

Information Disclosure: Protecting PHI and Proprietary Data

Information disclosure covers unauthorized exposure of sensitive data, most critically protected health information (PHI) but also proprietary algorithms, encryption keys, and network topology that could enable further attacks. Medical devices are frequent targets here because they often store or transmit PHI with weaker protections than the hospital's core EHR systems, unencrypted local storage, cleartext network protocols, or verbose debug logging are common culprits found during security assessments. Encryption at rest and in transit, minimizing the data actually stored on the device, and disabling debug interfaces before production release are the standard mitigations, each of which needs to be verified rather than assumed during testing.

Denial of Service: Ensuring Availability of Life-Critical Functions

Denial of service (DoS) threats target the availability of a device's function, which is uniquely dangerous in medical devices because loss of availability can directly translate to loss of a life-sustaining or life-critical function, unlike in typical IT systems where DoS is primarily a business disruption. Attack vectors include network flooding against connected devices, resource exhaustion through malformed input, and exploiting error-handling paths that cause a crash or reboot loop. For life-critical devices, mitigations often include rate limiting and input validation on all external interfaces, graceful degradation to a safe state rather than a hard failure, and network segmentation so a compromised hospital network segment cannot directly flood the device.

Elevation of Privilege: Controlling Access in Hospital Environments

Elevation of privilege occurs when a user or process gains access rights beyond what they were authorized for, for example a clinical user account being used to reach service-technician-level configuration settings, or a compromised low-privilege process escalating to root on an embedded Linux platform. Hospital environments make this risk particularly acute because devices are often shared across many users with varying access levels, and service technicians frequently need elevated access for maintenance that should not be reachable from the clinical interface. Role-based access control with the principle of least privilege, separate authentication paths for clinical versus service functions, and hardened, minimal operating system images that remove unnecessary privileged binaries are the standard mitigations.

The 4-Step Medical Device Threat Modeling Process

Step 1: Decomposing the System (Data Flow Diagrams)

Before applying STRIDE, you need a data flow diagram (DFD) that maps every component, data store, external entity, and trust boundary in the device's ecosystem, the device itself, companion apps, cloud backends, hospital network interfaces, and any third-party integrations. Trust boundaries, the points where data crosses between components with different privilege or trust levels, are the most important elements to get right, because STRIDE threats are evaluated at each boundary crossing rather than in the abstract. Incomplete DFDs are the single most common root cause of an incomplete threat model, if a data flow or trust boundary is missing from the diagram, the threats that live there never get analyzed.

Step 2: Applying the STRIDE Mnemonic to Components

With the DFD complete, walk through each element, process, data store, data flow, and external entity, and systematically ask which of the six STRIDE categories apply to it, since not every category is relevant to every element type (data stores, for example, are rarely subject to spoofing but are highly relevant to tampering and information disclosure). This step should involve both security engineers and the design engineers who understand the component's actual implementation, because threats that look theoretical on paper are often either more or less exploitable once you understand the real technical constraints. The output is a threat list per component, each entry describing the specific attack scenario, not just the STRIDE category name.

Step 3: Risk Assessment and Mitigation Strategies

Each identified threat then needs to be scored for likelihood and severity, using a consistent methodology ideally shared with your ISO 14971 or TIR57 risk management file, so that security risk scoring and safety risk scoring speak the same language. Threats above your risk acceptability threshold require a defined mitigation, encryption, authentication, input validation, or a compensating control, and each mitigation needs an owner and a design change tracked through your normal engineering change process. Risk assessment output should also identify any risks the team decides to accept as-is, with documented rationale, since reviewers expect to see that residual risk was a deliberate decision, not an oversight.

Step 4: Validation and Traceability for Regulatory Audits

Every mitigation identified in Step 3 needs a corresponding verification test case that proves the control actually works, a claim of "we added authentication" is not evidence without a test report showing an unauthenticated access attempt was rejected. Build a traceability matrix that links each threat to its mitigation, to its test case, and to its test result, because this is precisely the chain FDA reviewers and internal auditors try to walk when evaluating your submission. Keep the threat model itself under document control and version it alongside the design, since a threat model that does not match the shipped architecture is worse than no threat model at all.

Common STRIDE Pitfalls in MedTech Submissions

The most frequent pitfalls we see are: DFDs that omit third-party components and cloud services because the manufacturer assumes those are "someone else's problem," threat models that stop at identification without carrying through to documented mitigations and test evidence, generic threat lists copied from a template without device-specific analysis, and threat models that are done once at concept phase and never updated as the design changes. Each of these produces a document that looks complete at a glance but falls apart under a reviewer's specific questions about a particular interface or data flow, which is where most cybersecurity deficiency letters originate.

Integrating STRIDE with AAMI TIR57 and ISO 14971

STRIDE output should not exist as a standalone artifact, it needs to feed directly into your TIR57 security risk assessment and, where a security threat could produce patient harm, into your ISO 14971 safety risk management file as well. The practical integration point is your risk register: each STRIDE-identified threat becomes a risk entry, scored using the same severity and likelihood scales as your safety risks, so a reviewer can see the full risk picture in one place rather than reconciling two disconnected documents. This is also where cross-functional review matters most, security engineers understand the attack surface, but clinical and safety engineers understand which technical consequences actually translate into patient harm.

Conclusion: From Threat Model to Secure Architecture

A STRIDE-based threat model is only valuable if it changes the design, threats identified but not mitigated, or mitigations claimed but not tested, provide little real protection and little real regulatory credibility. The manufacturers who get the most out of threat modeling treat it as a continuous design input, revisited at every major architecture change, tightly linked to their risk management file, and backed by verification evidence that a reviewer can trace end to end.

How Blue Goat Cyber Approaches STRIDE threat modeling medical devices

We treat STRIDE threat modeling medical devices as a regulated engineering workstream, not a one-time document drop. Every engagement is led by senior medical-device security engineers who have shipped 250+ FDA cybersecurity submissions across 510(k), De Novo, PMA, and EU MDR pathways. Here is how we run it end to end:

• Scoping against your device profile. We baseline connectivity, interfaces, data flows, and intended use before we touch a template - because reviewer expectations for a Class II wearable are not the same as a networked hospital platform.
• Standards mapping in writing. Every deliverable is traced to the February 2026 FDA premarket cybersecurity guidance, AAMI SW96, AAMI TIR57 / TIR97, IEC 81001-5-1, and ISO 14971 - with the citation in the artifact itself so reviewers do not have to guess.
• Evidence generated inside your QMS. Threat models, SBOMs, security risk assessments, and test reports are versioned under design controls so the traceability from requirement → test → residual risk holds up under audit.
• Independent testing where it counts. Penetration testing and vulnerability analysis are executed by a testing team that does not also write the design - the separation FDA reviewers increasingly expect on cyber devices.
• Deficiency-ready posture. We anticipate the RTA, AI-letter, and Major deficiency patterns FDA has issued over the past 24 months and pre-empt them in the initial submission, cutting the odds of a second review cycle.
• Postmarket handoff, not abandonment. Every premarket package leaves you with a working postmarket monitoring plan, CVD process, and update cadence so the evidence you shipped stays defensible after clearance.

If you want that treatment applied to your STRIDE threat modeling medical devices package, our FDA Premarket Cybersecurity Services and FDA Cybersecurity Deficiency Response engagements are the two most common entry points.

Frequently asked questions

Is STRIDE required by the FDA for medical device submissions?

The FDA does not mandate STRIDE by name, but its premarket cybersecurity guidance requires a documented, systematic threat identification process, and STRIDE is the most commonly used and best-recognized framework for meeting that expectation in a medical device submission. PASTA and LINDDUN are also acceptable and sometimes better suited to particular device types (LINDDUN, for example, is stronger for privacy-heavy analyses), but reviewers are most familiar with STRIDE output and it tends to produce the smoothest review. Whichever framework you choose, what actually matters to reviewers is that the process was applied consistently, is traceable to your architecture, and produced mitigations backed by verification evidence.

How do you create a Data Flow Diagram (DFD) for a medical device?

Start by identifying every component in the device's ecosystem: the device itself, any companion mobile or desktop apps, cloud backends, hospital network interfaces, and third-party integrations such as EHR connections or cloud analytics services. Map the data flows between them, and mark every point where data crosses between components with a different trust or privilege level as a trust boundary, since these boundaries are where STRIDE threats concentrate. Include data stores (local storage, databases, log files) and external entities (users, other systems) alongside processes, and validate the diagram against the actual implementation, not just the design intent, since undocumented debug interfaces or maintenance backdoors are common gaps between the two.

What is the difference between STRIDE and PASTA for MedTech?

STRIDE is a threat-centric framework that categorizes attacks by type and works best applied at the component and data-flow level to systematically enumerate what could go wrong. PASTA (Process for Attack Simulation and Threat Analysis) is a risk-centric, seven-stage methodology that starts from business and compliance objectives and builds toward attacker simulation, producing a more business-risk-oriented output that ties threats explicitly to impact. Many mature MedTech security programs use both together, STRIDE for the detailed technical threat enumeration during design, and PASTA-style business impact analysis to prioritize which threats matter most given the device's clinical context and regulatory exposure.

How does threat modeling relate to medical device risk management (ISO 14971)?

Threat modeling identifies specific attack scenarios; ISO 14971-based risk management evaluates whether those scenarios, and the harms they could cause, are acceptable and what needs to be done about them. The two processes should be linked directly: each threat identified through STRIDE becomes a candidate risk entry in your risk management file, scored using the same severity and probability criteria you use for other hazards, so security and safety risk are evaluated on a single, consistent scale. Without this link, a manufacturer can have a technically thorough threat model that never actually informs the risk acceptability decisions the FDA and ISO 14971 expect to see documented.

What level of detail does the FDA expect in a threat model?

The FDA expects a threat model detailed enough that a reviewer can independently verify the analysis covered every external interface, every trust boundary, and every category of threat relevant to that interface, generic or templated threat lists without device-specific detail are a common source of deficiency letters. Each identified threat should describe a specific, plausible attack scenario (not just "spoofing" as a category label), be scored for risk, tied to a specific mitigation, and backed by a test case demonstrating the mitigation works. Reviewers are also increasingly checking that the threat model reflects the actual shipped architecture, not an earlier design iteration, so version control and update history matter.

Where this fits in the cluster

This page sits downstream of our pillar resources on STRIDE threat modeling medical devices. If you arrived here from a different starting point, these are the most useful adjacent pages:

• Medical Device Threat Modeling
• 12 Critical Threat Modeling Gaps in Medical Device Submissions
• Secure MedTech Product Design Consulting
• The SPDF Playbook for FDA-Ready Medical Devices

Related from Blue Goat Cyber

• FDA Premarket Cybersecurity Services
• Medical Device Penetration Testing
• 12 Critical Threat Modeling Gaps in Medical Device Submissions
• FDA-Compliant SBOM Services
• The MedTech Cybersecurity Standards Decoder

Sources & primary references

• Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions. U.S. Food and Drug Administration (FDA)
• NIST SP 800-154: Guide to Data-Centric System Threat Modeling. NIST (National Institute of Standards and Technology)
• Principles and Practices for Medical Device Cybersecurity. International Medical Device Regulators Forum (IMDRF)

Talk to a regulatory cybersecurity team

If you are working through STRIDE threat modeling medical devices and want a second pair of eyes on your submission package, we ship cybersecurity deliverables for medical device manufacturers across 510(k), De Novo, PMA, and EU MDR pathways. Book a discovery session and we will walk your evidence with you.